$EXAM (ExamWorks Group, Inc.)

$EXAM {{ '2016-04-27T13:33:21+0000' | timeago}} • Announcement

Medical services company $EXAM said it agreed to be acquired by an affiliate of Leonard Green & Partners, L.P., for $35.05 per share in cash, representing a total transaction value of approximately $2.2Bil. $EXAM board approved the transaction and recommended the shareholders vote in favor of the deal. . The deal is expected to close in 3Q16.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$PMC {{ '2017-12-07T18:06:23+0000' | timeago}} • Announcement

$PMC announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of $WBA as a minority investor.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$CVS {{ '2017-12-04T21:29:13+0000' | timeago}} • Announcement

$CVS has agreed to acquire $AET for appox. $207 per share or approx. $69Bil. Including the assumption of $AET debt, the total value of the deal is $77Bil. The transaction is expected to close in the second half of 2018.

$LHCG {{ '2017-12-04T19:56:36+0000' | timeago}} • Announcement

$LHCG and Erlanger Health System have finalized a new JV to enhance home health and community-based services in Chattanooga and southeast Tennessee. The JV includes a Chattanooga facility, which will operate as Erlanger ContinuCare Home Health. $LHCG expects annualized revenue from this JV of approx. $7MM and no material effect to 2017 diluted EPS.

$LHCG {{ '2017-11-16T14:14:41+0000' | timeago}} • Announcement

$LHCG-$AFAM merger will create a nationwide provider of in-home healthcare services. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8Bil and adjusted EBITDA of approx. $145MM for the trailing 12-month period ended Sept. 30, 2017.

$LHCG {{ '2017-11-16T14:13:01+0000' | timeago}} • Announcement

$LHCG and $AFAM have agreed to combine in an all-stock merger of equals transaction. Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company.

$CVS {{ '2017-11-08T12:39:44+0000' | timeago}} • Webcast

For 4Q17, $CVS expects a negative free cash flow, as the company plans to settle the CMS payable associated with the 2016 plan year. Based on this the company maintains its FY17 guidance and continues to expect to produce free cash of between $6-6.4Bil

$CVS {{ '2017-11-08T12:33:21+0000' | timeago}} • Webcast

$CVS entered into a five-year agreement with $ANTM during 3Q17. Based on this, $CVS will offer its services to support $ANTM's new pharmacy benefit management company called IngenioRx, effective January 2020. The services include claims processing and prescription fulfillment through mail order and specialty pharmacies.

$CVS {{ '2017-11-08T12:24:47+0000' | timeago}} • Webcast

During 3Q17, $CVS experienced a negative effect of the three major hurricanes that hit Southern U.S. and Puerto Rico. The hurricanes along with retail weakness is what contributed to lower earnings during the quarter. The storm triggered a financial impact of approx. $55MM, which are costs primarily to cover insurance deductibles.

$CVS {{ '2017-11-06T18:42:25+0000' | timeago}} • Announcement

$CVS to bring next-day delivery from CVS Pharmacy locations beginning in early 2018. The company plans to offer free same-day delivery within hours in selected markets. $CVS continues to expand its partnership with Instacart to offer personal shopping at 2,600 CVS Pharmacy stores across the country.

Recent Transcripts

PETS (PetMed Express, Inc.)
Monday, January 22 2018 - 1:30pm
RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
LHCG (LHC Group, Inc.)
Monday, November 6 2017 - 4:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
PETS (PetMed Express, Inc.)
Monday, October 23 2017 - 12:30pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
PRSC (Providence Service Corp.)
Wednesday, August 9 2017 - 12:00pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm

AlphaGraphics you may like